Literature DB >> 34281359

Opioid Use Disorder Among Clients of Community Mental Health Clinics: Prevalence, Characteristics, and Treatment Willingness.

Allison J Ober1, Sarah B Hunter1, Colleen M McCullough1, Isabel Leamon1, Michael McCreary1, Ivan Beas1, Alanna Montero1, Derjung M Tarn1, Elizabeth Bromley1, Brian Hurley1, John Sheehe1, Jeremy Martinez1, Katherine E Watkins1.   

Abstract

OBJECTIVE: The authors examined the prevalence of co-occurring opioid use disorder and willingness to engage in treatment among clients of eight Los Angeles County Department of Mental Health outpatient clinics.
METHODS: Adults presenting for an appointment over a 2-week period were invited to complete a voluntary, anonymous health survey. Clients who indicated opioid use in the past year were offered a longer survey assessing probable opioid use disorder. Willingness to take medication and receive treatment also was assessed.
RESULTS: In total, 3,090 clients completed screening. Among these, 8% had a probable prescription (Rx) opioid use disorder and 2% a probable heroin use disorder. Of the clients with probable Rx opioid use or heroin use disorder, 49% and 25% were female, respectively. Among those with probable Rx opioid use disorder, 43% were Black, 33% were Hispanic, and 12% were White, and among those with probable heroin use disorder, 24% were Black, 22% were Hispanic, and 39% were White. Seventy-eight percent of those with Rx opioid use disorder had never received any treatment, and 82% had never taken a medication for this disorder; 39% of those with heroin use disorder had never received any treatment, and 39% had never received a medication. The strongest predictor of willingness to take a medication was believing that it would help stop opioid use (buprenorphine, β=13.54, p=0.003, and naltrexone long-acting injection, β=15.83, p<0.001).
CONCLUSIONS: These findings highlight the need to identify people with opioid use disorder and to educate clients in mental health settings about medications for these disorders.

Entities:  

Keywords:  Co-occurring disorders; Drug abuse; Mental health systems; Mental illness and opioid use disorder; Opioid use disorder medication

Mesh:

Substances:

Year:  2021        PMID: 34281359      PMCID: PMC8770719          DOI: 10.1176/appi.ps.202000818

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  40 in total

1.  Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study.

Authors:  Gilberto Gerra; Claudio Leonardi; Antonio D'Amore; Giovanni Strepparola; Roberto Fagetti; Cinzia Assi; Amir Zaimovic; Alfio Lucchini
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-11-23       Impact factor: 5.067

2.  Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.

Authors:  Paul M Roman; Amanda J Abraham; Hannah K Knudsen
Journal:  Addict Behav       Date:  2011-01-27       Impact factor: 3.913

Review 3.  Defining organizational capacity for public health services and systems research.

Authors:  Anne-Marie Meyer; Meredith Davis; Glen P Mays
Journal:  J Public Health Manag Pract       Date:  2012-11

4.  Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.

Authors:  Peter D Friedmann; Randall Hoskinson; Michael Gordon; Robert Schwartz; Timothy Kinlock; Kevin Knight; Patrick M Flynn; Wayne N Welsh; Lynda A R Stein; Stanley Sacks; Daniel J O'Connell; Hannah K Knudsen; Michael S Shafer; Elizabeth Hall; Linda K Frisman
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

5.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Authors:  Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  JAMA Netw Open       Date:  2020-02-05

6.  Changes in US Lifetime Heroin Use and Heroin Use Disorder: Prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Silvia S Martins; Aaron Sarvet; Julian Santaella-Tenorio; Tulshi Saha; Bridget F Grant; Deborah S Hasin
Journal:  JAMA Psychiatry       Date:  2017-05-01       Impact factor: 21.596

7.  Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.

Authors:  Helena B Hansen; Carole E Siegel; Brady G Case; David N Bertollo; Danae DiRocco; Marc Galanter
Journal:  J Behav Health Serv Res       Date:  2013-07       Impact factor: 1.505

8.  African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018.

Authors:  Debra Furr-Holden; Adam J Milam; Ling Wang; Richard Sadler
Journal:  Addiction       Date:  2020-09-15       Impact factor: 6.526

9.  Management of relapse in naltrexone maintenance for heroin dependence.

Authors:  Maria A Sullivan; Fatima Garawi; Adam Bisaga; Sandra D Comer; Kenneth Carpenter; Wilfrid N Raby; Stephen J Anen; Adam C Brooks; Huiping Jiang; Evaristo Akerele; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2007-08-02       Impact factor: 4.492

10.  The Readiness Ruler as a measure of readiness to change poly-drug use in drug abusers.

Authors:  Morten Hesse
Journal:  Harm Reduct J       Date:  2006-01-25
View more
  2 in total

1.  Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness.

Authors:  Derjung M Tarn; Kevin J Shih; Allison J Ober; Sarah B Hunter; Katherine E Watkins; Jeremy Martinez; Alanna Montero; Michael McCreary; Isabel Leamon; John Sheehe; Elizabeth Bromley
Journal:  Community Ment Health J       Date:  2022-07-29

2.  Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.

Authors:  Barbara Andraka-Christou; Cory Page; Victoria Schoebel; Jessica Buche; Rebecca L Haffajee
Journal:  Addict Sci Clin Pract       Date:  2022-08-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.